Immunocytokine Nhs-Il12
Small Intestine Cancer
National Cancer Institute (NCI)protein_peptidePhase 2Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 29/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Small Intestine Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | BB |
Etoposide Cancer Research UK | Phase 2 | BB |
Vincristine Sulfate Cancer Research UK | Phase 2 | BB |
Nivestim Cancer Research UK | Phase 2 | BB |
Carboplatin National Cancer Institute (NCI) | Phase 2 | B |
View all 49 →
Same molecule, other indications
Immunocytokine Nhs-Il12 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →